A randomised controlled trial to compare two different doses of maternal B12 supplementation in improving infant B12 deficiency and neurodevelopment
A randomised controlled trial to compare two different doses of maternal B12 supplementation in improving infant B12 deficiency and neurodevelopment
批准号:
MR/R020396/1
负责人:
Monica Lakhanpaul
金额:
$50.64万
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2018
资助国家:
英国
项目状态:
已结题
起止时间:
2018 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Vitamin B12, also called cobalamin, is a water-soluble vitamin that has a key role in the normal functioning of the brain and nervous system. Up to 74% women are reported deficient during antenatal period in some populations. Deficiency of B12 in newborns is problematic given the role Vitamin B12 plays in neuronal health (brain and nerve cells health) and in the development of foetal and infant brain. We propose this research to compare two different doses (a treatment dose in comparison with a dose known to just prevent further deficiency) of maternal Vitamin B12 supplementation in terms of their effectiveness in removing infant B12 deficiency and neurodevelopment.We propose to undertake a multi-centric trial in India and Nepal as these are countries where high incidence of deficiency is reported. We will recruit 720 pregnant women from the antenatal clinics of the department of Gynaecology and Obstetrics at Sitaram Bhartia institute of Science and Research, New Delhi and Paropakar Indrarajayalaxmi Maternity Hospital, Kathmandu, Nepal. The subjects will be recruited at their first presentation to the antenatal clinic and should be vegetarian as they are at high-risk of B12 deficiency. Mothers who are >35 years of age, are already on B12 supplementation, have multiple gestation, chronic medical conditions, known psychological illnesses or those who anticipate moving out of the city before/after delivery will be excluded from the study. Recruited mothers will be randomly allocated to 2 equal groups (360 each). Group 1 (Intervention) will receive daily 250 micrograms Vitamin B12 supplementation to the mother through pregnancy and up to 6 months post-partum. Group 2 (Control) will receive 50 micrograms Vitamin B12 supplementation to the mother through pregnancy and up to 6 months post-partum. The profile information of the mother including age, height, weight, ethnicity, education, socioeconomic status, maternal dietary assessment (by Food Frequency Questionnaire), intake of any supplements (iron, folate, Vitamin-D) etc. will be recorded. Vitamin B12 dosage will be provided at enrolment and then monthly to mothers. Mother's blood levels for Vitamin B12 status and other deficiencies will be drawn. Sampling for these biochemical tests will be combined with other routine tests at these stages to avoid any additional discomfort for the mother. At childbirth, the delivery and post-delivery course of the new-born will be monitored and documented for any problems potentially influencing neurodevelopment. After discharge, all neonates will be routinely followed with preventive and vaccination care as per standard protocols. During routine visits, anthropometric measurements including weight, length and head circumference will be recorded and signs of micronutrient deficiency (especially anaemia and rickets) will be noted. Any illnesses suffered by the child in the intervening period will be recorded. Supplementation of the mother in both groups will be stopped at 6 months after childbirth followed by evaluation at 9 months. The neurodevelopmental assessment and home environment assessment will be done by a developmental therapist and complementary feeding assessment by a nutritionist. Along with routine sampling for Hb screening at 9 months, infant B12 levels status will be determined. The assessment of the infant neurodevelopment scores, the biochemical measures of B12 status of the infant and those of the mother will then be compared between the two groups to see if the neurodevelopment and/or B12 status in the group receiving the higher dose (250 mcg) is better and safe. A positive or a negative result will generate scientific evidence on whether B12 should be supplemented in vegetarian pregnant women with a view to preventing B12 deficiency and its neurodevelopmental consequences in the infant. This will also allow the development of policies and frameworks for routine/wider usage of this supplement in high-risk populations
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Efficacy of maternal B12 supplementation in vegetarian women for improving infant neurodevelopment: protocol for the MATCOBIND multicentre, double-blind, randomised controlled trial.
素食女性补充 B12 对改善婴儿神经发育的功效:MATCOBIND 多中心、双盲、随机对照试验方案。
DOI:
10.1136/bmjopen-2019-034987
发表时间:
2020
期刊:
BMJ open
影响因子:
2.9
作者:
[Nagpal J]
通讯作者:
Nagpal J
327 Maternal B-12 supplementation in vegetarian pregnant women improves maternal B-12 status and infant neurodevelopment: The MATCOBIND multi-centric double-blind randomised-control-trial
327 素食孕妇补充 B-12 可改善母亲 B-12 状态和婴儿神经发育:MATCOBIND 多中心双盲随机对照试验
DOI:
10.1136/archdischild-2023-rcpch.486
发表时间:
2023
期刊:
影响因子:
--
作者:
[Nagpal J]
通讯作者:
Nagpal J
COVID-19 impacts on children under 5 in temporary accommodation-co-developing solutions from lockdown to the recovery phase-A mixed-methods study
-
批准号:ES/V016253/1
-
项目类别:Research Grant
-
资助金额:$67.26万
-
财政年份:2020
-
负责人:Monica Lakhanpaul
-
依托单位:
Integrated Health, education and environmental (HEE) intervention to optimise infant feeding practices through schools and Anganwadi networks in India
-
批准号:MR/P024114/1
-
项目类别:Research Grant
-
资助金额:$76.78万
-
财政年份:2017
-
负责人:Monica Lakhanpaul
-
依托单位:
国内基金
海外基金
登录
查看更多内容
槲皮素控释系统调控Mettl3/Per1修复氧化应激损伤促牙周炎骨再生及机制研究
-
批准号:82370921
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:徐袁瑾
-
依托单位:
肿瘤翻译调控蛋白调控大肠癌细胞转移能力的信号机制研究
-
批准号:81000952
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:马强
-
依托单位:
多肽树状物为载体的抗癌前体药物的合成和研究
-
批准号:81072530
-
项目类别:面上项目
-
资助金额:36.0万元
-
批准年份:2010
-
负责人:刘河
-
依托单位:
植物病毒壳体"智能"纳米载体靶向肿瘤细胞的研究
-
批准号:30973685
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2009
-
负责人:曾庆冰
-
依托单位:
高臭氧浓度下水稻颖花和粒重形成受阻及其成因-FACE研究
-
批准号:30871486
-
项目类别:面上项目
-
资助金额:29.0万元
-
批准年份:2008
-
负责人:杨连新
-
依托单位: